ReviewCNS drugs2007
Adverse effects of atypical antipsychotics : differential risk and clinical implications.
Review in CNS drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 8 syntheses or guidelines pooled it, 450 citations in OpenAlex.
- Effects of physical exercise on metabolic syndrome in psychotic disorders: A systematic review with meta-analysis of randomized controlled trials.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis.BMC psychiatry · 2019Pooled it
- Are Patients WithFrontiers in pharmacology · 2019Pooled it
- Wendan decoction (Traditional Chinese medicine) for schizophrenia.The Cochrane database of systematic reviews · 2017Pooled it
- Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature.Pediatric neurology · 2017Pooled it
- Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.PloS one · 2012Pooled it
- The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.Schizophrenia bulletin · 2010Guideline
- Pooled it
- Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT.Health technology assessment (Winchester, England) · 2021Trial
- The role of serious mental illness in motivation, participation and adoption of health behavior change among obese/sedentary Latino adults.Ethnicity & health · 2019Trial
- Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.The lancet. Psychiatry · 2018Trial
- Trial
- Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects.The international journal of neuropsychopharmacology · 2014Trial
- Symptom prevalence and pharmacological management of late-stage Parkinson's disease (LSPD): a cross-sectional, multinational survey.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- The Role of the Ketogenic Diet in Modulating Biochemical Pathophysiology in Psychiatric and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- Biomarker Variants of Dopamine Receptor Genes Influence the Binding Interaction Between Dopamine Receptor and Risperidone.Drug design, development and therapy · 2026Article
- Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.Frontiers in pharmacology · 2026Article
- Psychiatric Medications and QTc Prolongation in the Pediatric Population.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2025Article
- Evidence for the Role of the Mitochondrial ABC Transporter MDL1 in the Uptake of Clozapine and Related Molecules into the YeastPharmaceuticals (Basel, Switzerland) · 2024Article
- A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.Pharmacy (Basel, Switzerland) · 2024Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic drugs can be of great benefit in a range of psychiatric disorders, including schizophrenia and bipolar disorder, but all are associated with a wide range of potential adverse effects. These can impair quality of life, cause stigma, lead to poor adherence with medication, cause physical morbidity and, in extreme cases, be fatal. A comprehensive overview of tolerability requires a review of all available data, including randomised controlled trials (RCTs), observational studies and postmarketing surveillance studies. Assessing the relative tolerability of atypical antipsychotics is hampered by the paucity of RCTs that compare these drugs head-to-head, and limited and inconsistent reporting of adverse effect data that makes cross-study comparisons difficult. Despite methodological problems in assessment and interpretation of tolerability data, important differences exist between the atypical antipsychotics in the relative risk of acute extrapyramidal symptoms (highest risk: higher doses of risperidone), hyperglycaemia and dyslipidaemia (highest risk: clozapine and olanzapine), hyperprolactinaemia (highest risk: amisulpride and risperidone), prolongation of heart rate-corrected QT interval (QTc) [highest risk: ziprasidone and sertindole] and weight gain (highest risk: clozapine and olanzapine). Sedation, antimuscarinic symptoms, postural hypotension, agranulocytosis and seizures are more common with clozapine than with other atypical antipsychotics. The variation in their tolerability suggests that it is misleading to regard the atypical antipsychotics as a uniform drug class, and also means that the term 'atypical antipsychotic' has only limited usefulness. Differences between the atypical agents in terms of efficacy and pharmacodynamic profiles also support this view. As tolerability differs between specific conventional and atypical drugs, we conclude that broad statements comparing the relative risk of specific adverse effects between 'atypical' and 'conventional' antipsychotics are largely meaningless; rather, comparisons should be made between specific atypical and specific conventional drugs. Adverse effects are usually dose dependent and can be influenced by patient characteristics, including age and gender. These confounding factors should be considered in clinical practice and in the interpretation of research data. Selection of an antipsychotic should be on an individual patient basis. Patients should be involved in prescribing decisions and this should involve discussion about adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.